Race To Buy Huge Share Of India’s Piramal Said Led By Sanofi-Aventis
This article was originally published in PharmAsia News
Executive Summary
The unacknowledged scramble among drug makers to buy a controlling stake in India's Piramal Healthcare is reported to be led by French multinational Sanofi-Aventis. The Indian company continues to deny reports it seeks to sell a large stake, but sources familiar with the dealing say the French drug maker has completed due diligence and could close the deal soon. GlaxoSmithKline also has been mentioned as a suitor for the stake of members of the Piramal family that owned 49.55 percent of the firm as of the end of 2008. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.